Workflow
Carmell Therapeutics (CTCX)
icon
Search documents
Carmell Therapeutics (CTCX) - 2024 Q1 - Quarterly Report
2024-05-15 20:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 CARMELL CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organization ...
Carmell Announces Successful Closing of $3.0 Million Private Placement
Newsfilter· 2024-04-11 20:30
PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of its previously announced private placement with new and existing investors (the "Private Placement"). The Company received gross proceeds from the Private Placement of $3 million, excluding offering expenses. The Company issued and sold an aggregate amount of 1,331,452 shares of its common s ...
Carmell Announces $3.0 Million Private Placement
Newsfilter· 2024-04-04 12:30
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expens ...
Carmell Therapeutics (CTCX) - 2023 Q4 - Annual Report
2024-04-01 15:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 CARMELL CORPORATION (Exact Name of Registrant as Specified in its Charter) 2403 Sidney Street, Suite 300 Pittsburgh, Pennsylvania 15203 (Address of principal exec ...
Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary
Newsfilter· 2024-03-20 20:39
PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "Th ...
Carmell to Host Investor Webinar, "Unveiling the Secretome: On the Eve of Product Launch" Featuring Key Opinion Leaders in the Medical Aesthetics Field
Newsfilter· 2024-03-18 19:16
PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell" or the "Company"), today announced it will host an Investor Webinar titled "Unveiling the Secretome: On the Eve of Product Launch" on March 20, 2024 at 3:00 PM ET to discuss Carmell Secretome™, the biggest technological revolution in regenerative skin and haircare to the fast-growing ~$500 billion aesthetics industry. To register, click here. The event will fe ...
Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024
Newsfilter· 2024-02-26 13:30
PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell" or the "Company"), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.) product for commercial launch in March 2024. Additionally, the Company is in advanced stages of development and testing of 9 other skincare products anticipated to launch over Spring and Summer 2024. The Carmell skincare product por ...
Carmell Therapeutics (CTCX) - 2023 Q3 - Quarterly Report
2023-11-14 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 CARMELL CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organiza ...
Carmell Therapeutics (CTCX) - 2023 Q2 - Quarterly Report
2023-08-13 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Carmell Corporation (Exact name of registrant as specified in its charter) Delaware 001-40228 86-1645738 (State or other jurisdiction of incorporation) (Commission File Num ...
Carmell Therapeutics (CTCX) - 2023 Q1 - Quarterly Report
2023-05-14 16:00
Alpha Healthcare Acquisition Corp. III (Exact name of registrant as specified in its charter) Page No. PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 1 Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022 1 Condensed Consolidated Statements of Operations (Unaudited) 2 Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) 3 Condensed Consolidated Statements of Cash Flows (Unaudited) 4 Notes to Cond ...